Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

244.86 -0.13 (-0.05%)
Streaming Delayed Price Updated: 12:05 PM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
I Correctly Predicted That These 15 Dow Jones Stocks Would Boost Their Payouts in 2025. Here's Why It Can Happen Again in 2026. ↗
The Dow is chock-full of high-quality companies that pay growing dividends. 
Via The Motley Fool
Topics Stocks
News headline image
Resilience in the Face of the Patent Cliff: Johnson & Johnson Forecasts Landmark 2026 Growth
NEW BRUNSWICK, N.J. – Johnson & Johnson (NYSE: JNJ) has signaled a definitive turning point in its corporate evolution, issuing a robust 2026 financial outlook that defies the gravity of the... 
Via MarketMinute
Topics Earnings Economy Intellectual Property
News headline image
Johnson &amp; Johnson Analyst Raises Price Target On Several Tailwinds In 2026 ↗
Johnson & Johnson stated that there are at least three tailwinds for the Innovative Medicines business through 2026. 
Via Benzinga
Johnson & Johnson (NYSE:JNJ) Beats Q4 Estimates but Stock Dips on 2026 Guidance ↗
Via Chartmill
The Davos Pivot: Trump’s Tariff U-Turn Sends Markets Into a Greenland Glow ↗
Via Chartmill
Topics Government
News headline image
This 2.4%-Yielding Dividend King Remains As Healthy As Ever ↗
Johnson & Johnson had a strong year. 
Via The Motley Fool
Topics Bonds
News headline image
S&amp;P 500 Jumps Over 1% As Trump Withdraws EU Tariff Threat: Investor Sentiment Improves, Fear &amp; Greed Index Remains In &#39;Neutral&#39; Zone ↗
U.S. stocks rise as Trump withdraws tariff threats, Johnson & Johnson beats earnings expectations, and all S&P sectors close positively. 
Via Benzinga
Topics Government Stocks World Trade
News headline image
Is This Dividend King Stock a Buy After a Major Development? ↗
After a strong performance in 2025, Johnson & Johnson is starting the new year right. 
Via The Motley Fool
Topics Government World Trade
News headline image
J&J Forecasts $100 Billion Milestone for 2026 as Trump Drug Pricing Deals Reshape the Pharma Landscape
NEW BRUNSWICK, N.J. — In a landmark display of resilience and strategic pivoting, Johnson & Johnson (NYSE: JNJ) reported fourth-quarter 2025 revenues of $24.56 billion on Wednesday, January 21, 2026,... 
Via MarketMinute
Topics Earnings Economy Government
News headline image
Johnson & Johnson (JNJ) Earnings Call Transcript ↗
Johnson & Johnson (JNJ) Earnings Call Transcript 
Via The Motley Fool
Topics Earnings World Trade
Discover the top S&P500 movers in Wednesday's pre-market session. ↗
Via Chartmill
News headline image
Johnson & Johnson Posts Q4 2025 Revenue Beat, EPS Comes Up Short ↗
Johnson & Johnson reported Q4 2025 revenue of $24.6 billion, beating expectations, while EPS came in at $2.46, just below forecasts. 
Via Talk Markets
News headline image
Johnson & Johnson reports Q4 and Full-Year 2025 results
From Johnson & Johnson
Via Business Wire
News headline image
Nasdaq, S&P 500 Futures Rebound, All Eyes On Trump’s Davos Speech: Why TSLA, NVDA, NFLX, AVR Are On Traders' Radar Today ↗
Retail sentiment on Stocktwits on SPY and QQQ turned ‘extremely bearish’. 
Via Stocktwits
Topics Artificial Intelligence ETFs Economy
Dow, Nasdaq, S&P 500 Futures Tick Higher After Wall Street’s Worst Day In 3 Months: Why NFLX, AAPL, CRVS, GME, UAL Are In Focus Today ↗
Via Stocktwits
Topics Stocks
News headline image
The Titan’s Balance: Johnson & Johnson Reaches Record Highs Amidst Legal Hurdles and Med-Tech Transformation
As the healthcare industry looks toward 2026, Johnson & Johnson (NYSE: JNJ) stands at a historic crossroads, reinforcing its reputation as the ultimate bellwether for the global healthcare sector. On... 
Via MarketMinute
Topics Bankruptcy Lawsuit World Trade
News headline image
The New Titan of Wellness: Kimberly-Clark’s $48.7 Billion Kenvue Acquisition Reshapes Consumer Staples
In a bold move to transcend its identity as a legacy paper commodities giant, Kimberly-Clark (NYSE: KMB) has launched a massive $48.7 billion bid to acquire Kenvue (NYSE: KVUE), the consumer health... 
Via MarketMinute
Topics Initial Public Offering Supply Chain
News headline image
The M&A Renaissance: 2026 Set to Eclipse a Record-Breaking 2025 as AI and Regulatory Clarity Drive Deal Supercycle
As the global financial markets enter the first month of 2026, the dealmaking environment has shifted from a tentative recovery into a full-scale renaissance. Following a monumental 2025 that saw... 
Via MarketMinute
Topics Artificial Intelligence Credit Cards Economy
News headline image
The High-Stakes Balancing Act: Johnson & Johnson Braces for Q4 Earnings Amid Patent Cliffs and MedTech Expansion
As the opening bell approaches on January 21, 2026, all eyes on Wall Street are fixed on Johnson & Johnson (NYSE: JNJ), which is set to report its fourth-quarter and full-year 2025 financial results.... 
Via MarketMinute
Topics Bankruptcy Earnings Economy
News headline image
Johnson & Johnson Near 52-Week High As CAPLYTA Data Boosts Sentiment ↗
Johnson & Johnson's stock approaches its 52-week high due to positive Phase 3 CAPLYTA trial data, strong earnings momentum, and favorable market sentiment as it nears an upcoming earnings report. 
Via Talk Markets
News headline image
How To Earn $500 A Month From Johnson &amp; Johnson Stock Ahead Of Q4 Earnings ↗
Johnson & Johnson (NYSE: JNJ) to release Q4 earnings on Jan. 21, with analysts expecting $2.47/share. Recent news includes positive results for cancer drug and dividend yield of 2.38%. 
Via Benzinga
News headline image
Option Volatility And Earnings Report For January 20 - 23
Earnings season ramps up this week with some big names set to report. This week we have Netflix, Intel, Johnson & Johnson, Freeport McMoran and 3M Company all reporting in what shapes as a busy and... 
Via Barchart.com
News headline image
Johnson &amp; Johnson&#39;s $10 Billion Test: 2026 Outlook Could Make Or Break JNJ Heading Into Q4 ↗
Johnson & Johnson is set to report its Q4 results on Wednesday, facing one of the most important transitions in its modern history. 
Via Benzinga
News headline image
The New Era of Johnson & Johnson: A 2026 Deep-Dive Research Feature
As of January 19, 2026, Johnson & Johnson (NYSE: JNJ) stands as a radically different enterprise than the one most investors recognized just three years ago. Following the successful spin-off of its... 
Via Finterra
Topics Artificial Intelligence Bankruptcy Economy
News headline image
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever ↗
Income investors can rely on these stocks. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Wall Street’s Comeback King: Citigroup Shatters M&A Records as Jane Fraser Sets a High Bar for 2026
Citigroup Inc. (NYSE: C) has emerged from its multi-year restructuring with a historic performance in its investment banking division, reporting record-breaking M&A advisory revenue for the 2025 fiscal... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
Wall Street Renaissance: Goldman Sachs Posts Record $9.3 Billion in Fees as Dealmaking Roars Back
On January 15, 2026, Goldman Sachs (NYSE: GS) silenced critics of its strategic pivot by reporting a powerhouse fourth-quarter performance for 2025, headlined by a staggering $9.34 billion in annual... 
Via MarketMinute
Topics Credit Cards Earnings Economy
News headline image
Citigroup Shakes Up Wall Street with Record M&A Revenue as Global Dealmaking Thaws
In a definitive signal that the era of stagnant dealmaking has come to a close, Citigroup (NYSE:C) has reported record-breaking M&A advisory revenue for the fiscal year 2025. The results, unveiled on... 
Via MarketMinute
Topics Economy
News headline image
"Animal Spirits" Return: Morgan Stanley Signals M&A Renaissance as Healthcare and Industrials Lead Shifting Landscape
As 2026 begins, the global mergers and acquisitions (M&A) market is witnessing a profound "renaissance," driven by a confluence of stabilizing interest rates, record levels of corporate cash, and a... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Johnson &amp; Johnson Drug Slows Blood Cancer, Extends Survival In Pretreated Patients ↗
Johnson & Johnson reports Phase 3 results showing Tecvayli reduced disease progression and deaths in multiple myeloma patients, beating standard treatments with manageable side effects. 
Via Benzinga
Topics Death
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.